Harrow, Inc.

Harrow, Inc. is a leading U.S. eyecare pharmaceutical company dedicated to the discovery, development, and commercialization of ophthalmic pharmaceutical products. Headquartered in Nashville, Tennessee, the company's mission is to empower eyecare professionals with innovative, accessible, and affordable solutions that enhance patient care and improve vision outcomes, making ophthalmic pharmaceutical products available to millions of Americans annually.

Harrow offers a comprehensive portfolio of prescription and non-prescription ophthalmic pharmaceutical products designed to manage a wide range of conditions, including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, and glaucoma. The company's product offerings include FDA-approved branded therapies such as VEVYE, IHEEZO, TRIESENCE, FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, ILEVRO, MAXITROL, MAXIDEX, VIGAMOX, BYOOVIZ, and OPUVIZ, alongside a specialized compounding business operating under the ImprimisRx brand. Harrow distinguishes itself as the first U.S. ophthalmic pharmaceutical company to provide both compounded and FDA-approved products, utilizing a vertically integrated model that combines a pharmaceutical commercialization engine with in-house compounding pharmacy infrastructure.

Led by founder, Chairman, and CEO Mark L. Baum, Harrow, Inc. has demonstrated significant growth and strategic evolution. The company officially changed its corporate name from "Harrow Health, Inc." to "Harrow, Inc." in September 2023 to reflect its exclusive focus on eyecare pharmaceuticals. Harrow reported record financial results for Q4 and full-year 2025, with revenues of $89.1 million and $272.3 million respectively, marking year-over-year increases of 33% and 36%. The company continues to expand its market presence, recently announcing an add-on offering of $50.0 million in senior unsecured notes in March 2026 to support ongoing growth initiatives.